Utility of [18 F]FLT-PET to Assess Treatment Response in Trastuzumab-Resistant and Trastuzumab-Sensitive HER2-Overexpressing Human Breast Cancer Xenografts-Reference-Cited by-同舟云学术

Utility of [18 F]FLT-PET to Assess Treatment Response in Trastuzumab-Resistant and Trastuzumab-Sensitive HER2-Overexpressing Human Breast Cancer Xenografts

Published:2014-07-18 Issue:1 Volume:17 Page:119-128
ISSN:1536-1632
Container-title:Molecular Imaging and Biology
language:en
Short-container-title:Mol Imaging Biol

Author:

Whisenant Jennifer G.,McIntyre J. Oliver,Peterson Todd E.,Kang Hakmook,Sánchez Violeta,Manning H. Charles,Arteaga Carlos L.,Yankeelov Thomas E.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11307-014-0770-z.pdf

Reference36 articles.

1. Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838–47

2. Dean-Colomb W, Esteva FJ (2008) Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 44:2806–12

3. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413–28

4. Murphy CG, Morris PG (2012) Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 23:765–76

5. Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models;Biomedicines;2023-07-25

2. Mathematical Model of Triple-Negative Breast Cancer in Response to Combination Chemotherapies;Bulletin of Mathematical Biology;2022-12-21

3. Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer;Cancers;2022-02-17

4. Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography;Journal of Controlled Release;2020-08

5. Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models;Contrast Media & Molecular Imaging;2019-09-22